A trial of lenzilumab for acute graft versus host disease (RATinG)

This is a trial of lenzilumab for people with high risk acute graft versus host disease.

There are 2 types of graft versus host disease (GvHD):

• acute GvHD (aGvHD)

• chronic GvHD (cGvHD)

This trial is open to people with acute GvHD who:

• have had a stem cell transplant from another person (allogeneic transplant) and

• are to have treatment with steroids to treat the acute GvHD

You pronounce lenzilumab as lens-ill-lu-mab.